Survodutide for the Treatment of Obesity Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial

Funding

The SYNCHRONIZE-CVOT is funded by Boehringer Ingelheim. Dr Platz has received support from Novartis and scPharmaceuticals for consulting work (paid to Brigham and Women’s Hospital); has received research support from the NIH, American Heart Association, and AstraZeneca (paid to Brigham and Women’s Hospital); and has served on the clinical trial steering committee of clinical trials funded by Boehringer Ingelheim. Dr Platz is employed by AstraZeneca R&D, effective October 20, 2025. Dr Kaplan has served as a consultant for Altimmune, Amgen, AstraZeneca, Boehringer Ingelheim, Cytoki, Johnson and Johnson, Kallyope, Eli Lilly, Novo Nordisk, Optum Health, Oxford Medical Products, Perspectum, and Pfizer; has received research support from the U.S. National Institutes of Health and Ethicon; and has served on the executive committees of clinical trials funded by Boehringer Ingelheim, Eli Lilly and Oxford Medical Products. Dr le Roux has received grants from the EU Innovative Medicine Initiative, the Irish Research Council, the Science Foundation Ireland, Anabio, and the Health Research Board; has served on advisory boards and speaker panels for Novo Nordisk, Roche, Herbalife, GI Dynamics, Eli Lilly, Johnson and Johnson, Gila, Irish Life Health, Boehringer Ingelheim, Currax, Zealand Pharma, Keyron, AstraZeneca, Arrowhead Pharma, Amgen, AbbVie, Metsera, Nymble, Olympus, and Rhythm Pharma; is the Chair of the Irish Society for Nutrition and Metabolism; has received stock options as payment for scientific advisory board functions from Metsera and Nymble; and provides obesity clinical care in the My Best Weight clinic and Beyond BMI clinic and is a co-owner of these clinics. Dr Wharton has served on advisory boards or received honoraria from Abbvie, Amgen, AstraZeneca, Bausch Health Canada, Boehringer Ingelheim, Eli Lilly, Merck, Metsera, NGX, Novo Nordisk, Regeneron, and Vimy; has received clinical trials/research support from Amgen, AstraZeneca, Bausch Health Canada, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, and Pfizer; and has received academic/other support from McMaster University, York University, University of Toronto, and Obesity Canada. Drs Startseva, Fey, Hussain, and Brueckmann are employees of Boehringer Ingelheim International GmbH. Dr Burger is an employee of Boehringer Ingelheim Pharma GmbH and Co KG. Dr Kosiborod has received research grant funding (payments to institution) from AstraZeneca, Boehringer Ingelheim, and Pfizer; consultant/advisory board fees (payments to institution) from 35Pharma, Alnylam, Amgen, Applied Therapeutics, Arrowhead Pharmaceuticals, AstraZeneca, Bayer, Boehringer Ingelheim, Corcept Therapeutics, Cytokinetics, Dexcom, Eli Lilly, Esperion Therapeutics, Imbria Pharmaceuticals, Janssen, Lexicon Pharmaceuticals, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pfizer, Pharmacosmos, Regeneron, Roche, Sanofi, scPharmaceuticals, Structure Therapeutics, Vifor Pharma, and Youngene Therapeutics; other research support (data analytical center fees—payments to institution) from AstraZeneca and Vifor Pharma; honorarium (payments to institution) from AstraZeneca, Boehringer Ingelheim, and Novo Nordisk; stock options (personal) from Artera Health and Saghmos Therapeutics; and employment with AstraZeneca R and D, effective January 6, 2025. Dr Bozkurt has served as a consultant or advisor for ABIOMED/Johnson and Johnson, Bayer, Boehringer Ingelheim, Cardurion, Cytokinetics, Eli Lilly, Medtronic, Merck, Idorsia, Novo Nordisk, Regeneron, Renovacor, Roche, Salubris, Sanofi-Aventis, scPharmaceuticals, Vifor, and Respicardia/Zoll.